Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(24 sites) United States
City of Hope, Duarte, California City of Hope, Huntington Beach, California City of Hope, Irvine, California Levine Cancer Institute - Charlotte, Charlotte, North Carolina Thomas Jefferson University Research Facility, Philadelphia, Pennsylvania SCRI Oncology Partners - PPDS, Nashville, Tennessee University of Texas MD Anderson Cancer Center, Houston, Texas University of Utah - Huntsman Cancer Institute - PPDS, Salt Lake City, Utah NEXT Virginia, Fairfax, Virginia France
EDOG Institut de Cancerologie de l'Ouest - PPDS, Saint-Herblain, Loire-Atlantique Institut Claudius Regaud - PPDS, Toulouse Gustave Roussy, Villejuif Germany
Charité - Universitätsmedizin Berlin (CBF) - Hindenburgdamm 30, Berlin Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden Netherlands
Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis, Amsterdam South Korea
Chungbuk National University Hospital, Cheongju-si CHA Bundang Medical Center, CHA University, Seongnam-si Seoul National University Hospital, Seoul Spain
Hospital Regional Universitario de Malaga - Hospital General, Málaga, Malaga Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON, Barcelona Hospital Universitario Ramon y Cajal, Madrid Hospital Universitario Virgen del Rocio, Seville Taiwan
National Taiwan University Hospital, Taipei Taipei Veterans General Hospital, Taipei